Median-based incremental cost-effectiveness ratios with censored data

Heejung Bang; Hongwei Zhao

doi:10.1080/10543406.2015.1052482

Median-based incremental cost-effectiveness ratios with censored data

Heejung Bang, Hongwei Zhao

Public Health Sciences

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.

Original language	English (US)
Journal	Journal of Biopharmaceutical Statistics
DOIs	https://doi.org/10.1080/10543406.2015.1052482
State	Accepted/In press - Nov 11 2015

Keywords

Censoring
cost-effectiveness analysis
ICER
median

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology
Statistics and Probability

Access to Document

10.1080/10543406.2015.1052482

Fingerprint Dive into the research topics of 'Median-based incremental cost-effectiveness ratios with censored data'. Together they form a unique fingerprint.

Cite this

@article{12720d2793da4cf1855cc378d7e07333,

title = "Median-based incremental cost-effectiveness ratios with censored data",

abstract = "Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.",

keywords = "Censoring, cost-effectiveness analysis, ICER, median",

author = "Heejung Bang and Hongwei Zhao",

year = "2015",

month = nov,

day = "11",

doi = "10.1080/10543406.2015.1052482",

language = "English (US)",

journal = "Journal of Biopharmaceutical Statistics",

issn = "1054-3406",

publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Median-based incremental cost-effectiveness ratios with censored data

AU - Bang, Heejung

AU - Zhao, Hongwei

PY - 2015/11/11

Y1 - 2015/11/11

N2 - Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.

AB - Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.

KW - Censoring

KW - cost-effectiveness analysis

KW - ICER

KW - median

UR - http://www.scopus.com/inward/record.url?scp=84947206112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947206112&partnerID=8YFLogxK

U2 - 10.1080/10543406.2015.1052482

DO - 10.1080/10543406.2015.1052482

M3 - Article

C2 - 26010599

AN - SCOPUS:84947206112

JO - Journal of Biopharmaceutical Statistics

JF - Journal of Biopharmaceutical Statistics

SN - 1054-3406

ER -

Median-based incremental cost-effectiveness ratios with censored data

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this